Most of the currently ongoing clinical trials for pancreatic cancer treatment are evaluating anti-PD1 antibodies in combination with cytotoxic drugs, other mAbs or antibody-drug conjugates, cancer vaccines or PARP inhibitors (Table 6). The gene discussed is PDCD1; the disease is pancreatic neoplasm.